Shamburg News · 8-K filed Nov 12, 2026, 4:17 PM EST

Electra Therapeutics Reports Third Quarter 2026 Financial Results and Portfolio Update

ETRA · Electra Therapeutics, Inc.

  • Earnings
  • Materiality: high

Electra Therapeutics reported a net loss of $23.9 million for the third quarter ended September 30, 2026, with research and development expenses of $17.3 million and general and administrative expenses of $7.8 million. Cash, cash equivalents, and marketable securities totaled $402.5 million as of September 30, 2026, including $320.0 million in net proceeds from its September 2026 IPO. The company expects its current cash position to support planned operations into 2029.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458464.

Written from the filing by Shamburg Markets. Figures are as reported by the company.